Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

9.255 +0.165 (+1.82%)
Streaming Delayed Price Updated: 2:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
From Certara
Via GlobeNewswire
News headline image
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For Certara ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Certara Stock ↗
 
Via Benzinga
News headline image
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? ↗
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
News headline image
Top movers in Friday's pre-market session ↗
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Certara Stock ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Markets Reel As Trump's Tariffs Hit — Magnificent 7 Set To Shed Almost $700 Billion ↗
Trump's new tariffs trigger selloff, framed as correction to trade imbalance. China faces 37% duties, EU 20%, Japan 24%. Tech stocks hit hard. 
Via Benzinga
Topics Government World Trade
News headline image
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making 
From Certara
Via GlobeNewswire
News headline image
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
McKemey joins Certara to accelerate growth of its strategic drug development solutions 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
News headline image
Certara Appoints John Reynders as New Independent Board Member
From Certara
Via GlobeNewswire
News headline image
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
From Certara
Via GlobeNewswire
News headline image
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through... 
From Certara
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.